Seres Therapeutics (NASDAQ:MCRB) Upgraded by ValuEngine to “Hold”

Seres Therapeutics (NASDAQ:MCRB) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday, ValuEngine reports.

MCRB has been the subject of several other reports. Jefferies Financial Group lowered their price target on Seres Therapeutics from $6.00 to $4.00 and set a “hold” rating for the company in a research report on Monday, July 1st. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a report on Tuesday, May 7th. Chardan Capital reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 17th. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Thursday, July 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Seres Therapeutics in a report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $10.25.

Shares of MCRB traded down $0.36 during midday trading on Thursday, hitting $2.42. 309,742 shares of the stock were exchanged, compared to its average volume of 354,925. Seres Therapeutics has a 52-week low of $2.02 and a 52-week high of $9.26. The stock’s fifty day moving average is $2.85. The firm has a market cap of $112.19 million, a price-to-earnings ratio of -1.00 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $8.61 million. Analysts expect that Seres Therapeutics will post -1.75 EPS for the current year.

In related news, Director Noubar Afeyan bought 8,888,888 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $19,999,998.00. Following the completion of the acquisition, the director now owns 15,141 shares in the company, valued at approximately $34,067.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 37.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC lifted its holdings in Seres Therapeutics by 33.1% during the 2nd quarter. ARK Investment Management LLC now owns 7,038,885 shares of the biotechnology company’s stock worth $22,665,000 after buying an additional 1,751,172 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in Seres Therapeutics by 491.7% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 4,843,074 shares of the biotechnology company’s stock worth $15,595,000 after buying an additional 4,024,575 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Seres Therapeutics by 504.5% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,843,074 shares of the biotechnology company’s stock worth $15,595,000 after buying an additional 4,041,880 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Seres Therapeutics by 5.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 307,930 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 17,194 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Seres Therapeutics by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 237,774 shares of the biotechnology company’s stock worth $1,074,000 after buying an additional 11,476 shares during the last quarter. Hedge funds and other institutional investors own 82.03% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Read More: What are popular green investing opportunities?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.